An "export-only" exception to pharmaceutical patents in Europe: Should the U.S. follow suit?

TY - JOUR

T1 - An "export-only" exception to pharmaceutical patents in Europe: Should the U.S. follow suit?

AU - Minssen, Timo

AU - Kesselheim, Aaron

AU - Darrow, Jonathan

PY - 2019/1/3

Y1 - 2019/1/3

N2 - A new European Union policy could increase the supply of legitimate pharmaceuticals in developing countries and thereby minimize the problem of counterfeit medicines, but many challenges remain. This paper describes the proposed European legislation and discusses its' potential strengths, weaknesses, opportunities and threats. Ultimately, we consider if the United States should consider similar policies.

AB - A new European Union policy could increase the supply of legitimate pharmaceuticals in developing countries and thereby minimize the problem of counterfeit medicines, but many challenges remain. This paper describes the proposed European legislation and discusses its' potential strengths, weaknesses, opportunities and threats. Ultimately, we consider if the United States should consider similar policies.

U2 - 10.1038/nbt.4324

DO - 10.1038/nbt.4324

M3 - Journal article

SN - 1087-0156

VL - 37

SP - 21

EP - 22

JO - Nature Biotechnology

JF - Nature Biotechnology

IS - 1

ER -